CSI Market
Sign In | Register

Bioadaptives Inc (BDPT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access BDPT quarterly Cash Flow →
Reviewing cash flow figures over time highlights how Bioadaptives Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-1.56
Depreciation & amortization0.00
Amortization of Other Assets0.03
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Real Estate0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.03
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt-0.13
Stockbased Compensation Related Party-
Share Based Compensation Related Party-
Stock Based Compensation-
Stock Based Compensation Related Party-
Nondebtor Reorganization Items Net Gain Loss On Settlement Of Other Claims-
Marketable Securities Gain Loss-
Amortization Of License-
Gain Loss Related To Litigation Settlement-
Loss On Settlement Of Debt-
Marketable Securities Unrealized Gain Loss-
Impairment Of Investments-
Impairment Of Inventory-
Amortization Of Other Intangible Assets-
Change In Fair Value Of Derivative Liabilities-
Deferred Compensation Arrangement With Individual Compensation Expense0.44
Extinguishment Of Debt Gain Loss Net Of Taxs-
Unrealized Gain Loss On Investments In Marketable Securities-
Accrual Of Consulting Fees0.58
Increase Decrease In Prepaid Expense And Other Current Assets-
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable0.00
Accounts Payable0.05
Increase (Decrease) in Accrued Liabilities0.00
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Prepaid Expense0.09
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-0.52
Investing Activities
Capital Expenditures-0.02
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.02
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.26
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Proceeds from Contributions from Parent0.00
Issuances / -repurchases of Pref. Stock0.30
Increase (Decrease) in Deposits0.00
Other financing activities net0.00
Other net-0.14
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents0.14
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.56
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.53
Total Cash Flow0.02
4 historic quarters locked

Sign in to unlock the full Bioadaptives Inc cash flow history.

Sign In Create Free Account

About Bioadaptives Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: April 14, 2026
  • Source: bdpt_10k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001640334-26-000718

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License